Wednesday, October 11, 2017

Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy

Following up on the last post, Dr. Mike Lawlor sent me this in an email:

"Audentes Therapeutics officially announced the dosing of the first patient for the X-linked myotubular myopathy treatment trial that we’ve been working on over the past few years.  We’ve been very involved in the translation from dogs to humans, and will be doing the human pathology work for the trial.  Here’s a link to that press release."

No comments: